Nanobiotix S.A. (NASDAQ:NBTX – Get Free Report) traded down 6.8% during mid-day trading on Thursday . The company traded as low as $3.18 and last traded at $3.28. 55,693 shares traded hands during trading, an increase of 174% from the average session volume of 20,299 shares. The stock had previously closed at $3.52.
Analyst Upgrades and Downgrades
Separately, Guggenheim started coverage on shares of Nanobiotix in a research note on Wednesday, August 28th. They issued a “buy” rating and a $12.00 price objective for the company.
View Our Latest Stock Analysis on NBTX
Nanobiotix Stock Performance
Nanobiotix Company Profile
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Featured Articles
- Five stocks we like better than Nanobiotix
- Dividend Payout Ratio Calculator
- Micron Stock Under $100: Seize the AI-Driven Upside
- When to Sell a Stock for Profit or Loss
- AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025
- How to Invest in Biotech Stocks
- SolarEdge Stock Climbs Back: Goldman Sachs Sees 40% Upside
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
